Welcome to our dedicated page for Gh Research Plc SEC filings (Ticker: GHRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission filings for GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharmaceutical company focused on mebufotenin-based therapies for treatment-resistant depression and related psychiatric conditions. As a foreign private issuer, GH Research submits annual reports on Form 20-F and furnishes current information on Form 6-K.
In its Form 6-K current reports, the company provides updates on quarterly and interim financial results, business developments, and clinical progress. These filings often include condensed consolidated interim financial statements prepared under IFRS, detailing research and development expenses, general and administrative expenses, finance income and expense, and accumulated deficits typical of an R&D-focused enterprise. Balance sheet information in these filings outlines cash, cash equivalents, other financial assets, marketable securities, and equity components such as share capital and additional paid-in capital.
GH Research also uses Form 6-K to furnish press releases and investor materials describing milestones in its GH001 and GH002 programs, including Phase 2b and Phase 2a trial results, open-label extension data, safety and tolerability profiles, and regulatory interactions with the U.S. Food and Drug Administration. Additional 6-Ks announce participation in scientific congresses such as ECNP, ASCP, ISBD, and ACNP, where abstracts and presentations related to GH001-TRD-201 and other trials are shared.
Through this filings page, users can access GH Research’s SEC-submitted documents as they are made available from EDGAR. AI-powered tools on the platform can help summarize lengthy financial and clinical disclosures, highlight key points from interim results, and make it easier to track how GH Research’s development programs and capital position evolve across reporting periods.
GH Research PLC director Duncan Moore filed an initial ownership report showing holdings of ordinary shares and several tranches of vested share options. He directly holds 14,600 ordinary shares and multiple option awards to acquire ordinary shares at an exercise price of 0.025 per share, with expirations ranging from 2030 to 2032. Some option grants are fully vested and exercisable, while others vest over time or within specified windows under the GH Research PLC Share Option Plan.
GH Research PLC filed an initial ownership report for Chief Operating Officer Cameron Aaron Luke, detailing his holdings of share options over Ordinary Shares. These options give him the right to buy Ordinary Shares at preset exercise prices before their expiration dates.
He holds options over 33,211 underlying Ordinary Shares at an exercise price of $21.3200 per share expiring on August 30, 2029, 17,500 shares at $0.0250 expiring on April 27, 2030, 25,000 shares at $5.8000 expiring on January 1, 2032, 200,000 shares at $0.0250 expiring on November 25, 2031, and 100,000 shares at $0.0250 expiring on May 16, 2032.
Footnotes state that one grant is already fully vested and exercisable, while the others vest 25% on specified dates, with the remaining 75% vesting in equal monthly installments over three years.
GH Research PLC director Dermot John Hanley filed an initial ownership report listing his existing equity position in the company. The filing shows direct ownership of 2,432 Ordinary Shares as of March 18, 2026.
Hanley also holds several tranches of Share Options (Right to Buy) over Ordinary Shares with an exercise price of 0.0250 per share and expirations ranging from September 26, 2030 to September 3, 2032. These options cover 6,633, 5,508, 5,532, 50,000 and 4,667 underlying Ordinary Shares, respectively. Footnotes indicate the options are fully vested or vesting over time and may be exercised within specified multi‑year windows under the GH Research PLC Share Option Plan.
GH Research PLC executive Halle Magnus Clemensen, Managing Director for Ireland, filed an initial ownership report showing direct holdings of 118,354 Ordinary Shares. He also holds three grants of Share Options (Right to Buy) over 17,500, 150,000 and 50,000 underlying Ordinary Shares, each with an exercise price of 0.0250 per share and expirations in 2030, 2031 and 2032, respectively. For these options, 25% vests on specified initial dates, with the remainder vesting in equal monthly installments over three years.
GH Research PLC director Michael Forer reported his initial holdings, consisting of ordinary shares and multiple option grants. He holds 45,509 ordinary shares directly. He also holds fully vested share options over 6,633, 5,508 and 5,532 ordinary shares, each with an exercise price of 0.0250 per share and expirations in 2030 and 2031.
Additional option awards cover 50,000 ordinary shares expiring in 2031 and 4,667 ordinary shares expiring in 2032, also at an exercise price of 0.0250. Some of these options are fully vested and exercisable, while others vest over time or within specified windows under the GH Research PLC Share Option Plan.
GH Research PLC Chief Executive Officer Velichka Valcheva reported her existing holdings of share options over the company’s ordinary shares. These options cover 50,000 underlying shares at an exercise price of $10.83 per share expiring on August 22, 2031, and 35,000 underlying shares at $7.59 per share expiring on February 1, 2032.
She also holds two larger grants, each over 300,000 underlying ordinary shares with a $0.025 exercise price, expiring on November 25, 2031, and May 16, 2032. For each grant, 25% vested on a specified date, with the remaining 75% vesting in equal monthly installments over three years.
GH Research PLC VP, Finance Julie Ryan filed an initial statement of ownership showing multiple share option awards over ordinary shares. The holdings include options over 50,487 shares at an exercise price of $12.3200 per share expiring on June 4, 2029, and three additional grants over 17,500, 150,000, and 30,000 shares at an exercise price of $0.0250 per share with expirations on April 27, 2030, November 25, 2031, and May 16, 2032. Footnotes state one grant is fully vested and exercisable, while others vest 25% on specified dates with the remaining portions vesting in equal monthly installments over three years.
GH Research PLC director Florian Schonharting has filed an initial ownership report showing direct holdings of 14,824,419 Ordinary Shares. This Form 3 does not report any recent purchases or sales; it simply records his existing ownership position in the company.
GH Research PLC reported that full Phase 2b results for its inhaled mebufotenin therapy GH001 in treatment-resistant depression have been published in JAMA Psychiatry, with a supporting post hoc analysis accepted by Psychopharmacology Bulletin.
In the randomized, double-blind, placebo-controlled trial, GH001 given via a single-day individualized dosing regimen produced a large improvement in depression scores, with a least-squares mean MADRS reduction from baseline of −15.5 points versus placebo at Day 8 and 57.5% of GH001-treated patients in remission compared with 0% on placebo. The post hoc analysis of 40 GH001-treated patients found efficacy was largely independent of the number of prior lifetime antidepressant treatment failures: Day 8 remission rates ranged from 53.9% to 63.6% across subgroups with 2, 3, 4, or ≥5 prior failures and remained high at Month 6 (61.5%–85.7%). Safety data showed mostly mild or moderate adverse events, with no serious or severe events, deaths, or discontinuations.
GH Research PLC filed a Form 6-K stating it will participate in a fireside chat during the Stifel 2026 Virtual CNS Forum. The event is scheduled to take place virtually from March 17-18, 2026. The report is signed by Julie Ryan, Vice President, Finance.